Trial Profile
Use of Tolvaptan to Treat SIADH-induced Hyponatremia in Selected Patients With Acute Neurological Injuries
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2018
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Hyponatraemia
- Focus Therapeutic Use
- 20 Sep 2018 Status changed from withdrawn prior to enrolment to discontinued as major protocol revision needed, current project terminated after enrollment of 25 patients.
- 16 Nov 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 11 Sep 2015 New trial record